NASDAQ:ENDP - Endo International Stock Price, Price Target & More

Question 1

What is Endo International's stock symbol?

Answer

Endo International trades on the NASDAQ under the ticker symbol "ENDP."

Question 2

How were Endo International's earnings last quarter?

Answer

Endo International plc (NASDAQ:ENDP) issued its quarterly earnings results on Tuesday, May, 8th. The company reported $0.67 EPS for the quarter, beating the Zacks' consensus estimate of $0.55 by $0.12. The business had revenue of $700.53 million for the quarter, compared to analysts' expectations of $691.94 million. Endo International had a negative net margin of 75.58% and a positive return on equity of 143.46%. The business's quarterly revenue was down 32.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.23 earnings per share. View Endo International's Earnings History.

Question 3

When is Endo International's next earnings date?

Answer

Endo International is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Endo International.

Question 4

What guidance has Endo International issued on next quarter's earnings?

Answer

Endo International updated its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share guidance of $2.15-2.55 for the period, compared to the Thomson Reuters consensus estimate of $2.34. The company issued revenue guidance of $2.6-2.8 billion, compared to the consensus revenue estimate of $2.74 billion.

Question 5

What price target have analysts set for ENDP?

Answer

20 brokers have issued twelve-month price objectives for Endo International's stock. Their forecasts range from $7.00 to $16.00. On average, they anticipate Endo International's share price to reach $9.4063 in the next twelve months. View Analyst Ratings for Endo International.

Question 6

What are Wall Street analysts saying about Endo International stock?

Answer

Here are some recent quotes from research analysts about Endo International stock:

1. According to Zacks Investment Research, "Endo’s guidance for 2018 was way below expectations. The generics business is under tremendous pressure due to the loss of marketing exclusivity for the first-to-file products ezetimibe tablets and quetiapine ER tablets in the first half of 2017. The branded pharmaceuticals business was impacted by continued generic competition for established products, product divestitures and ceasing shipments of Opana ER and this is expected to continue further. Endo withdrew opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA’s request in June 2017. The company divested its non-core assets such as Belbuca and restructured its pain franchise to focus particularly on specialty branded business. However, we expect challenging business conditions for the company in 2018. Shares have underperformed the industry over a year." (5/1/2018)
2. Cantor Fitzgerald analysts commented, "Takeaways from the quarter: 1) Executing well against its stated objectives in U.S. generics, during 4Q17, the U.S. generics segment launched six products and submitted two regulatory filings. In 2017, the U.S. generics segment launched 17 products and ENDP made 12 regulatory submissions. As of 12/31/17, ENDP had ~100 ANDAs (~1/3 FTF/FTM) pending with the FDA. 2) Sterile Injectables is a growing franchise. Sterile Injectables revenue increased 16% YOY. This increase was driven by Adrenalin. 3) Important sterile injectable drugs include Vasostrict and Adrenalin. ENDP reported 2017 Vasostrict sales of $400MM and Adrenalin sales of $77MM. 4) As of 12/31/17, ENDP had $987MM in unrestricted cash, net debt of ~$7.3B and a net leverage ratio of 4.6x. 5) 4Q17 cash provided by operating activities was $132MM, compared to $84MM of net cash provided by operating activities in 2016. 6) Cellulite could be a big opportunity for ENDP. RELEASE-1 And RELEASE-2 Phase 3 trials looking at Xiaflex for the treatment cellulite were initiated. Topline data are expected 1Q19. ENDP plans to submit all the data in 2019. ENDP expects to commercialize the product on its own, but would consider strategic alternatives. 7) ENDP thinks that the generic market seems more stable, but it is still early in 2018." (2/27/2018)
3. Mizuho analysts commented, "We Lower PT to $12 from $14; Buy on Valuation Rating Buy Previous Rating No Change Price (1/02) $8.10 Price Target $12.00 Previous Price Target $14.00 Summary We reiterate our Buy rating but lower our PT to $12 from $14. We think 2018 guidance may prove disappointing, but we continue to view the stock as undervalued." (1/3/2018)

Question 7

Are investors shorting Endo International?

Answer

Endo International saw a decline in short interest in April. As of April 30th, there was short interest totalling 32,207,296 shares, a decline of 4.7% from the April 13th total of 33,791,139 shares. Based on an average daily volume of 4,032,480 shares, the short-interest ratio is presently 8.0 days. Currently, 16.1% of the shares of the company are short sold.

Question 8

Who are some of Endo International's key competitors?

Answer

Some companies that are related to Endo International include GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD) and Supernus Pharmaceuticals (SUPN).

Question 9

Who are Endo International's key executives?

Answer

Endo International's management team includes the folowing people:

Mr. Paul V. Campanelli, Pres, CEO & Director (Age 56)
Mr. Blaise Coleman, Exec. VP & CFO (Age 44)
Mr. Terrance J. Coughlin, Exec. VP & COO (Age 52)
Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 46)
Ms. Carrie A. Nichol CPA, VP, Controller & Chief Accounting Officer (Age 38)

Question 10

Has Endo International been receiving favorable news coverage?

Answer

Media coverage about ENDP stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Endo International earned a news impact score of 0.11 on Accern's scale. They also assigned news coverage about the company an impact score of 45.92 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Question 11

Who are Endo International's major shareholders?

Answer

Endo International's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BNP Paribas Arbitrage SA (1.47%), Diamond Hill Capital Management Inc. (0.49%), New York State Common Retirement Fund (0.25%), Alps Advisors Inc. (0.20%), Schroder Investment Management Group (0.19%) and American International Group Inc. (0.18%). Company insiders that own Endo International stock include Blaise Coleman, Matthew Joseph Maletta, Nancy J Hutson, Paul Campanelli, Roger H Kimmel and Terrance J Coughlin. View Institutional Ownership Trends for Endo International.

Question 12

Which institutional investors are selling Endo International stock?

Answer

ENDP stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., New York State Common Retirement Fund, Van ECK Associates Corp, New York State Teachers Retirement System, American International Group Inc., California State Teachers Retirement System, Rhumbline Advisers and Gamco Investors INC. ET AL. View Insider Buying and Selling for Endo International.

Question 13

Which institutional investors are buying Endo International stock?

Answer

ENDP stock was purchased by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Schroder Investment Management Group, Alps Advisors Inc., Diamond Hill Capital Management Inc., Systematic Financial Management LP, Flinton Capital Management LLC, Tyers Asset Management LLC and Riverhead Capital Management LLC. Company insiders that have bought Endo International stock in the last two years include Blaise Coleman, Matthew Joseph Maletta, Paul Campanelli and Terrance J Coughlin. View Insider Buying and Selling for Endo International.

Question 14

How do I buy shares of Endo International?

Answer

Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

Question 15

What is Endo International's stock price today?

Answer

One share of ENDP stock can currently be purchased for approximately $5.95.

Question 16

How big of a company is Endo International?

Answer

Endo International has a market capitalization of $1.34 billion and generates $3.47 billion in revenue each year. The company earns $-2,035,430,000.00 in net income (profit) each year or $3.84 on an earnings per share basis. Endo International employs 3,039 workers across the globe.

Question 17

How can I contact Endo International?

Answer

Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		675 (Vote Outperform)
Underperform Votes:		625 (Vote Underperform)
Total Votes:		1,300

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.10	2.10	2.22	2.15
Ratings Breakdown:	1 Sell Rating(s) 16 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 16 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 12 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 15 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$9.4063	$9.4063	$10.4688	$11.8125
Price Target Upside:	58.09% upside	64.44% upside	54.63% upside	70.45% upside

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/13/2018	Oppenheimer	Reiterated Rating	Hold		Low
5/8/2018	Canaccord Genuity	Set Price Target	Hold	$7.00	Low
5/8/2018	Cantor Fitzgerald	Set Price Target	Hold	$7.00	High
4/4/2018	Mizuho	Downgrade	Buy ➝ Neutral	$12.00 ➝ $7.00	High
3/10/2018	Barclays	Set Price Target	Hold	$9.00	Low
3/5/2018	BMO Capital Markets	Lower Price Target	Market Perform ➝ Market Perform	$10.00 ➝ $9.00	High
2/28/2018	Gabelli	Downgrade	Buy ➝ Hold		High
2/26/2018	JMP Securities	Downgrade	Outperform ➝ Market Perform		Low
2/14/2018	B. Riley	Initiated Coverage	Buy ➝ Buy	$10.00	High
1/2/2018	Leerink Swann	Initiated Coverage	Outperform ➝ Outperform	$12.00	High
12/12/2017	Guggenheim	Initiated Coverage	Neutral ➝ Neutral	$8.50	Low
11/10/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$7.00	N/A
11/10/2017	Citigroup	Lower Price Target	Neutral	$9.00 ➝ $7.00	N/A
11/10/2017	Royal Bank of Canada	Lower Price Target	Sector Perform ➝ Sector Perform	$9.00 ➝ $8.00	N/A
9/28/2017	Goldman Sachs	Initiated Coverage	Sell ➝ Sell	$7.00	High
8/10/2017	Morgan Stanley	Lower Price Target	Equal Weight	$12.00 ➝ $8.00	Low
8/10/2017	Cowen	Reiterated Rating	Hold	$16.00	High
8/9/2017	Deutsche Bank	Set Price Target	Buy	$15.00 ➝ $13.00	Low
6/14/2017	William Blair	Reiterated Rating	Market Perform		Low
6/9/2017	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$22.00 ➝ $15.00	High
1/31/2017	Susquehanna Bancshares	Upgrade	Neutral ➝ Positive		N/A
1/20/2017	JPMorgan Chase	Downgrade	Overweight ➝ Neutral	$20.00	N/A
9/29/2016	Northland Securities	Upgrade	Market Perform ➝ Outperform	$27.00	N/A
8/9/2016	UBS	Reiterated Rating	Buy	$30.00	N/A

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	$0.54	$0.59	$0.56
Q2 2018	4	$0.49	$0.60	$0.54
Q3 2018	4	$0.53	$0.60	$0.56
Q4 2018	4	$0.44	$0.63	$0.56
Q1 2019	1	$0.58	$0.58	$0.58
Q2 2019	1	$0.59	$0.59	$0.59
Q3 2019	1	$0.60	$0.60	$0.60
Q4 2019	1	$0.62	$0.62	$0.62

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/6/2018		$0.54					N/A
5/8/2018	3/31/2018	$0.55	$0.67	$691.94 million	$700.53 million	View	Listen
2/27/2018	Before Market	$0.62	$0.77	$762.29 million	$768.64 million	View	Listen
11/9/2017	Q3	$0.85	$0.91	$794.93 million	$786.90 million	View	N/A
8/8/2017	6/30/2017	$0.74	$0.93	$832.66 million	$875.73 million	View	Listen
5/9/2017	Q1 17	$1.10	$1.23	$1.0235 billion	$1.0380 billion	View	Listen
2/28/2017	Q416	$1.63	$1.77	$1.17 billion	$1.2420 billion	View	Listen
11/8/2016	Q316	$0.81	$1.01	$862.47 million	$894.30 million	View	Listen
8/8/2016	Q216	$0.74	$0.86	$873.50 million	$921.00 million	View	Listen
5/5/2016	Q116	$1.04	$1.08	$960.96 million	$963.54 million	View	Listen
2/29/2016	Q415	$1.27	$1.36	$1.07 billion	$1.07 billion	View	Listen
11/5/2015	Q315	$1.00	$1.02	$736.16 million	$746.00 million	View	Listen
8/10/2015	Q215	$1.02	$1.08	$727.45 million	$735.00 million	View	Listen
5/11/2015	Q115	$1.07	$1.17	$714.42 million	$714.00 million	View	Listen
3/2/2015	Q414	$1.13	$1.16	$780.44 million	$800.00 million	View	Listen
11/5/2014	Q314	$0.99	$1.15	$721.11 million	$764.00 million	View	Listen
7/31/2014	Q214	$0.90	$1.06	$644.60 million	$719.00 million	View	Listen
5/1/2014	Q114	$0.84	$0.92	$608.86 million	$595.00 million	View	Listen
2/28/2014	Q413	$0.93	$0.96	$620.90 million	$584.95 million	View	Listen
11/7/2013	Q313	$1.11	$1.34	$695.63 million	$715.00 million	View	Listen
8/6/2013	Q2 2013	$1.15	$1.42	$721.01 million	$766.51 million	View	Listen
5/7/2013	Q1 2013	$1.08	$1.09	$737.79 million	$709.00 million	View	Listen
2/28/2013	Q4 2012	$1.54	$1.62	$807.98 million	$801.06 million	View	Listen
11/5/2012	Q312	$1.26	$1.28	$788.53 million	$750.50 million	View	N/A
8/7/2012		$1.19	$1.27			View	N/A
5/1/2012		$0.86	$0.87			View	N/A
2/24/2012		$1.32	$1.40			View	N/A
10/27/2011		$1.28	$1.25			View	N/A
8/9/2011		$1.06	$1.05			View	N/A
4/28/2011		$1.00	$1.00			View	N/A
2/28/2011		$0.97	$1.06			View	N/A
11/1/2010	Q3 2010	$0.85	$0.87			View	N/A
7/30/2010	Q2 2010	$0.80	$0.81			View	N/A
4/30/2010	Q1 2010	$0.75	$0.74			View	N/A
2/22/2010	Q4 2009	$0.68	$0.81			View	N/A
10/29/2009	Q3 2009	$0.64	$0.63			View	N/A
7/30/2009	Q2 2009	$0.67	$0.73			View	N/A
4/29/2009	Q1 2009	$0.60	$0.67			View	N/A
2/27/2009	Q4 2008	$0.59	$0.66			View	N/A
10/30/2008	Q3 2008	$0.52	$0.61			View	N/A
7/31/2008	Q2 2008	$0.49	$0.57			View	N/A
4/30/2008	Q1 2008	$0.47	$0.51			View	N/A
2/22/2008	Q4 2007	$0.44	$0.50			View	N/A

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/15/2017	Blaise Coleman	CFO	Buy	6,500	$7.89	$51,285.00	13,729
8/15/2017	Matthew Joseph Maletta	EVP	Buy	3,000	$8.02	$24,060.00	6,984
8/14/2017	Paul Campanelli	CEO	Buy	6,500	$7.71	$50,115.00	213,620
8/10/2017	Terrance J Coughlin	COO	Buy	20,000	$7.70	$154,000.00	181,369
3/16/2017	Paul Campanelli	CEO	Buy	2,300	$10.72	$24,656.00	207,120
3/9/2017	Nancy J. Hutson	Director	Sell	5,325	$10.82	$57,616.50
11/15/2016	Roger H. Kimmel	Director	Sell	14,000	$17.38	$243,320.00
5/11/2016	Arthur J Higgins	Director	Buy	5,000	$13.80	$69,000.00	50,623
5/10/2016	Arthur J Higgins	Director	Buy	11,000	$15.42	$169,620.00	45,623
5/10/2016	Paul Campanelli	Insider	Buy	13,000	$15.53	$201,890.00	201,069
3/17/2016	William Spengler	Director	Buy	1,000	$29.20	$29,200.00	48,835
3/16/2016	William Spengler	Director	Buy	1,000	$35.24	$35,240.00	47,835
3/14/2016	Roger H Kimmel	Director	Buy	1,125	$41.94	$47,182.50	72,237
3/7/2016	Matthew Joseph Maletta	VP	Buy	500	$44.48	$22,240.00	1,000
3/7/2016	Silva Rajiv De	CEO	Buy	2,250	$44.50	$100,125.00	250,705
3/1/2016	Nancy J. Hutson	Director	Sell	3,413	$42.19	$143,994.47	39,990
11/12/2015	Shane Cooke	Director	Buy	4,000	$57.13	$228,520.00	10,179
11/11/2015	Michael Hyatt	Director	Sell	8,000	$55.48	$443,840.00	251,599
11/11/2015	Paul Campanelli	insider	Buy	2,100	$55.69	$116,949.00	15,367
11/11/2015	Silva Rajiv De	CEO	Buy	9,006	$55.52	$500,013.12	13,697
11/11/2015	Suketu Upadhyay	CFO	Buy	4,450	$56.37	$250,846.50	17,740
11/11/2015	Susan Hall	EVP	Buy	1,000	$55.35	$55,350.00	7,515
6/16/2015	Arthur J Higgins	Director	Buy	2,500	$81.10	$202,750.00
4/8/2015	Caroline B Manogue	VP	Sell	105,562	$91.90	$9,701,147.80
11/14/2014	Suketu Upadhyay	CFO	Buy	3,700	$66.94	$247,678.00
8/5/2014	Arthur J Higgins	Director	Buy	3,500	$65.65	$229,775.00
6/9/2014	John Delucca	Director	Sell	6,764	$68.83	$465,566.12
5/29/2014	Caroline B Manogue	VP	Sell	175,033	$72.02	$12,605,876.66
5/1/2014	John Delucca	Director	Sell	8,094	$66.31	$536,713.14	21,596
4/1/2014	John Delucca	Director	Sell	10,384	$68.46	$710,888.64	21,596
3/10/2014	Arthur Higgins	Director	Buy	5,000	$73.00	$365,000.00	5,000
3/10/2014	Ivan Gergel	EVP	Sell	75,637	$72.47	$5,481,413.39	27,649
8/26/2013	Caroline Manogue	VP	Sell	145,592	$39.40	$5,736,324.80	46,422
8/8/2013	Roger Kimmel	Director	Buy	5,478	$36.50	$199,947.00	51,914
4/9/2013	Caroline B Manogue	VP	Sell	35,000	$35.00	$1,225,000.00
11/12/2012	David Holveck	CEO	Buy	7,425	$26.84	$199,287.00

Date	Headline
	Q2 2018 EPS Estimates for Endo International plc (ENDP) Reduced by Analyst www.americanbankingnews.com - May 23 at 6:44 AM
	Critical Comparison: Endo International (ENDP) and Its Competitors www.americanbankingnews.com - May 22 at 9:17 PM
	Endo International plc (ENDP) Expected to Announce Quarterly Sales of $680.67 Million www.americanbankingnews.com - May 20 at 1:54 AM
	Brokerages Anticipate Endo International plc (ENDP) Will Announce Earnings of $0.55 Per Share www.americanbankingnews.com - May 18 at 11:23 PM
	Broadfin pumps $50M into Raleigh's BDSI www.bizjournals.com - May 17 at 7:02 PM
	BidaskClub Upgrades Endo International (ENDP) to "Sell" www.americanbankingnews.com - May 16 at 11:04 AM
	Endo International plc Expected to Post Q2 2018 Earnings of $0.60 Per Share (ENDP) www.americanbankingnews.com - May 16 at 7:16 AM
	US state attorneys general sue Purdue Pharma over opioid epidemic www.cnbc.com - May 15 at 5:53 PM
	BRIEF-Paulson & Co Ups Share Stake In Discovery, Endo International www.reuters.com - May 15 at 5:53 PM
	Endo International (ENDP) Rating Reiterated by Oppenheimer www.americanbankingnews.com - May 14 at 12:42 PM
	Endo International plc (ENDP) Short Interest Down 4.7% in April www.americanbankingnews.com - May 13 at 1:40 AM
	FY2022 Earnings Forecast for Endo International plc Issued By Gabelli (ENDP) www.americanbankingnews.com - May 11 at 11:53 AM
	FY2020 EPS Estimates for Endo International plc Boosted by Analyst (ENDP) www.americanbankingnews.com - May 11 at 11:47 AM
	Endo International plc (ENDP) Given Average Rating of "Hold" by Analysts www.americanbankingnews.com - May 10 at 4:59 PM
	FY2020 EPS Estimates for Endo International plc (ENDP) Decreased by Piper Jaffray www.americanbankingnews.com - May 10 at 9:07 AM
	Endo International plc (ENDP) to Post Q2 2018 Earnings of $0.51 Per Share, Leerink Swann Forecasts www.americanbankingnews.com - May 10 at 6:54 AM
	Q2 2018 Earnings Forecast for Endo International plc (ENDP) Issued By Piper Jaffray www.americanbankingnews.com - May 9 at 8:48 AM
	Edited Transcript of ENDP earnings conference call or presentation 8-May-18 11:30am GMT finance.yahoo.com - May 9 at 8:11 AM
	Wired News - Lannett Announced Acquisition of 23 Approved Drug Product Applications from Endo International's Subsidiary finance.yahoo.com - May 9 at 8:11 AM
	Endo International (ENDP) Given a $7.00 Price Target at Canaccord Genuity www.americanbankingnews.com - May 8 at 6:26 PM
	Endo up 5% on Q1 results; reiterates guidance seekingalpha.com - May 8 at 5:47 PM
	Endo International (ENDP) Given a $7.00 Price Target by Cantor Fitzgerald Analysts www.americanbankingnews.com - May 8 at 3:28 PM
	Endo International (ENDP) Releases Quarterly Earnings Results www.americanbankingnews.com - May 8 at 12:13 PM
	Endo International (ENDP) Issues FY18 Earnings Guidance www.americanbankingnews.com - May 8 at 9:36 AM
	ENDO INTERNATIONAL PLC www.streetinsider.com - May 8 at 8:09 AM
	BRIEF-Endo Posts Q1 Adj. Earnings $0.67/Shr From Continuing Operations www.reuters.com - May 8 at 8:09 AM
	Earnings Reaction History: Endo International plc, 54.5% Follow-Through Indicator, 12.9% Sensitive www.nasdaq.com - May 8 at 8:09 AM
	Endo International (ENDP) Tops Q1 EPS by 12c, Affirms Gudiance www.streetinsider.com - May 8 at 8:09 AM
	Endo Reports First-Quarter 2018 Financial Results finance.yahoo.com - May 8 at 8:09 AM
	Endo shares rise 5% after Q1 profit, revenue beats finance.yahoo.com - May 8 at 8:09 AM
	Endo beats as Xiaflex sales, injectables business grow finance.yahoo.com - May 8 at 8:09 AM
	Drugmaker Endo posts wider quarterly loss finance.yahoo.com - May 8 at 8:09 AM
	Endo International (ENDP) Rating Lowered to Strong Sell at ValuEngine www.americanbankingnews.com - May 3 at 10:55 PM
	$687.14 Million in Sales Expected for Endo International plc (ENDP) This Quarter www.americanbankingnews.com - May 3 at 4:01 AM
	UPDATE 2-Indivior's Q1 profit slips, shares fall on top drug let-down www.reuters.com - May 2 at 8:15 AM
	Endo International (ENDP) Rating Increased to Hold at Zacks Investment Research www.americanbankingnews.com - May 1 at 12:26 PM
	Zacks: Analysts Expect Endo International plc (ENDP) Will Post Earnings of $0.54 Per Share www.americanbankingnews.com - May 1 at 9:18 AM
	Endo International (ENDP) Scheduled to Post Earnings on Tuesday www.americanbankingnews.com - May 1 at 5:50 AM
	Endo Pharmaceuticals Earnings Preview seekingalpha.com - April 30 at 8:15 AM
	Blog Exposure - Endo International to Acquire Somerset Therapeutics and its Affiliate Wintac Ltd finance.yahoo.com - April 30 at 8:15 AM
	Collagenase Clostridium Histolyticum For The Investigational Treatment Of Cellulite To Be Featured During The Hot ... www.prnewswire.com - April 28 at 8:21 AM
	Endo International (ENDP) to Acquire Somerset Therapeutics for $190M www.streetinsider.com - April 28 at 8:21 AM
	Collagenase Clostridium Histolyticum For The Investigational Treatment Of Cellulite To Be Featured During The Hot Topics Symposium At The Aesthetic Meeting 2018 finance.yahoo.com - April 27 at 8:24 AM
	Endo International plc (ENDP) Sees Large Decline in Short Interest www.americanbankingnews.com - April 27 at 2:58 AM
	Endo International to acquire Somerset Therapeutics for $190M seekingalpha.com - April 26 at 5:21 PM
	Endo to Acquire Somerset Therapeutics and Business of Affiliate Wintac Limited finance.yahoo.com - April 26 at 5:21 PM
	$190M deal: Endo buying North Jersey specialty pharma company finance.yahoo.com - April 26 at 5:21 PM
	ENDO Arm Gets Health Canada Nod for Treatment www.baystreet.ca - April 23 at 5:18 PM
	Paladin Labs Inc. Announces Launch of New Indication for XIAFLEX® (Collagenase Clostridium Histolyticum), Broadening Its Use to the Treatment of Appropriate Patients with Peyronie's Disease finance.yahoo.com - April 23 at 8:10 AM
	Paladin Labs Announces the Launch of Unisom® Snore Relief, the Only Natural Health Product Throat Spray Available in Canada to Help Relieve Symptoms Associated with Snoring finance.yahoo.com - April 19 at 8:09 AM

NASDAQ:ENDP - Endo International Stock Price, Price Target & More

About Endo International (NASDAQ:ENDP)

Receive ENDP News and Ratings via Email

Industry, Sector and Symbol

Debt

Price-To-Earnings

Sales & Book Value

Profitability

Miscellaneous

Endo International (NASDAQ:ENDP) Frequently Asked Questions

What is Endo International's stock symbol?

How were Endo International's earnings last quarter?

When is Endo International's next earnings date?

What guidance has Endo International issued on next quarter's earnings?

What price target have analysts set for ENDP?

What are Wall Street analysts saying about Endo International stock?

Are investors shorting Endo International?

Who are some of Endo International's key competitors?

Who are Endo International's key executives?

Has Endo International been receiving favorable news coverage?

Who are Endo International's major shareholders?

Which institutional investors are selling Endo International stock?

Which institutional investors are buying Endo International stock?

How do I buy shares of Endo International?

What is Endo International's stock price today?

How big of a company is Endo International?

How can I contact Endo International?

MarketBeat Community Rating for Endo International (ENDP)

Analyst Ratings

Endo International (NASDAQ:ENDP) Price Target and Consensus Rating

Endo International (NASDAQ:ENDP) Consensus Price Target History

Endo International (NASDAQ:ENDP) Analyst Ratings History

Earnings

Endo International (NASDAQ:ENDP) Earnings History and Estimates Chart

Endo International (NASDAQ:ENDP) Earnings Estimates

Endo International (NASDAQ ENDP) Earnings History by Quarter

Dividends

Endo International (NASDAQ:ENDP) Dividend History by Quarter

Insider Trades

Endo International (NASDAQ ENDP) Insider Trading and Institutional Ownership History

Endo International (NASDAQ ENDP) Insider Trading History

Headlines

Endo International (NASDAQ ENDP) News Headlines

SEC Filings

Endo International (NASDAQ:ENDP) SEC Filings

Social Media

Financials

Endo International (NASDAQ:ENDP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Endo International (NASDAQ ENDP) Stock Chart for Wednesday, May, 23, 2018